BET degraders for improving colorectal cancer therapy

BET 降解剂可改善结直肠癌治疗

基本信息

  • 批准号:
    10946894
  • 负责人:
  • 金额:
    $ 41.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-10-09 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the US. Developing novel and more effective CRC therapies is an unmet biomedical need as most of advanced and metastatic CRCs that progress after initial therapies respond poorly to therapeutic treatment. The bromodomain and extra-terminal domain (BET) family proteins such as BRD4 are epigenetic readers that control expression of key oncogenic proteins that drive CRC initiation and progression. Targeting the BET family proteins using small-molecule inhibitors has emerged as a promising therapeutic approach. However, BET inhibitors (BETi) as single agents are generally ineffective against epithelial cancers including CRCs. The molecular mechanisms underlying the anticancer activity of BET-targeting agents are not well understood. Recently, a new class of agents that induce rapid degradation of BET proteins has been developed. Our preliminary studies reveal that two such BET degraders (BETd), BETd260 and BETd246, are much more potent than other BET-targeting agents in CRC cells and patient-derived xenografts (PDXs). We identified a novel, on-target mechanism of action of BETd in transcriptionally activating Death Receptor 5 (DR5), a key component of the extrinsic apoptotic pathway. Importantly, the induction of DR5 is essential for the cell-killing and chemosensitization effects of BETd, and responsible for increased BETd sensitivity in a subset of CRCs with an activating mutation in Speckle-type POZ protein (SPOP), a subunit of the E3 ubiquitin ligase of BET proteins. Furthermore, our data suggest BETd have robust immunogenic effects by inducing DR5-mediated immunogenic cell death (ICD). A combination of BETd260 and anti-PD-1 antibody was well tolerated and nearly eradicated mouse CT26 syngeneic tumors in a DR5-dependent manner. Based on these findings, we hypothesize that BETd improve CRC therapies by inducing DR5-mediated CRC cell killing and antitumor immunity. Aim 1. Identify the mechanism and biomarkers of the potent anticancer activity of BETd in CRC cells; Aim 2. Determine the therapeutic efficacy of BETd against therapy-refractory and metastatic CRCs; Aim 3. Delineate and harness the immunogenic effects of BETd to improve CRC therapies. The proposed studies are expected to provide new mechanistic insights and establish key preclinical parameters for using BETd to develop precision and personalized therapies against therapy-refractory and incurable CRCs. In the long run, these studies may lead to new and improved therapies against CRCs and other types of cancer.
项目总结/摘要 结直肠癌(CRC)是美国癌症相关死亡的主要原因之一。开发新型 更有效的CRC治疗是一个未满足的生物医学需求,因为大多数晚期和转移性CRC, 初始治疗后的进展对治疗性治疗反应不佳。布罗莫结构域和额外末端 结构域(BET)家族蛋白如BRD 4是控制关键致癌基因表达的表观遗传阅读器, 蛋白质驱动CRC启动和进展。使用小分子靶向BET家族蛋白 抑制剂已经成为一种有前途的治疗方法。然而,BET抑制剂(BETi)作为单一药剂 通常对包括CRC在内的上皮癌无效。的分子机制 BET靶向剂的抗癌活性还没有被很好地理解。最近,一类新的诱导剂, 已经开发了BET蛋白质的快速降解。我们的初步研究表明,两个这样的BET 降解剂(BETd),BETd 260和BETd 246,在CRC细胞中比其他BET靶向剂有效得多 和患者来源的异种移植物(PDX)。我们确定了一种新的,对目标的作用机制,BETd在 转录激活死亡受体5(DR 5),其是外源性凋亡途径的关键组分。 重要的是,DR 5的诱导对于BETd的细胞杀伤和化学增敏作用至关重要,并且 在斑点型POZ中具有激活突变的CRC亚组中负责增加BETd敏感性 蛋白(SPOP),BET蛋白的E3泛素连接酶的亚基。此外,我们的数据表明, 通过诱导DR 5介导的免疫原性细胞死亡(ICD)产生强大的免疫原性作用。的组合 BETd 260和抗PD-1抗体耐受性良好,并且几乎根除了小鼠CT 26同源肿瘤。 DR 5依赖性方式。基于这些发现,我们假设BETd通过以下方式改善CRC治疗: 诱导DR 5介导的CRC细胞杀伤和抗肿瘤免疫。目标1.确定机制和生物标志物 BETd在CRC细胞中的有效抗癌活性;目的2.确定BETd对以下疾病的治疗效果: 难治性和转移性CRC;目的3.描述和利用BETd的免疫原性作用, 改善CRC疗法。预计拟议的研究将提供新的机制见解,并建立 使用BETd开发精确和个性化治疗的关键临床前参数, 难治性和不可治愈的CRCs。从长远来看,这些研究可能会导致新的和改进的疗法 针对CRCs和其他类型的癌症。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lin Zhang其他文献

Lin Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lin Zhang', 18)}}的其他基金

Role of necroptosis in colorectal cancer therapy
坏死性凋亡在结直肠癌治疗中的作用
  • 批准号:
    10891823
  • 财政年份:
    2023
  • 资助金额:
    $ 41.82万
  • 项目类别:
Targeting CDK7 in high-grade serous ovarian carcinoma
靶向 CDK7 治疗高级别浆液性卵巢癌
  • 批准号:
    10275795
  • 财政年份:
    2021
  • 资助金额:
    $ 41.82万
  • 项目类别:
BET degraders for improving colorectal cancer therapy
BET 降解剂可改善结直肠癌治疗
  • 批准号:
    10372054
  • 财政年份:
    2021
  • 资助金额:
    $ 41.82万
  • 项目类别:
Targeting CDK7 in high-grade serous ovarian carcinoma
靶向 CDK7 治疗高级别浆液性卵巢癌
  • 批准号:
    10683737
  • 财政年份:
    2021
  • 资助金额:
    $ 41.82万
  • 项目类别:
Targeting CDK7 in high-grade serous ovarian carcinoma
靶向 CDK7 治疗高级别浆液性卵巢癌
  • 批准号:
    10461935
  • 财政年份:
    2021
  • 资助金额:
    $ 41.82万
  • 项目类别:
Role of necroptosis in colorectal cancer therapy
坏死性凋亡在结直肠癌治疗中的作用
  • 批准号:
    10410392
  • 财政年份:
    2019
  • 资助金额:
    $ 41.82万
  • 项目类别:
Molecular mechanism and preclinical development of BETi and PARPi combination therapy
BETi和PARPi联合疗法的分子机制和临床前开发
  • 批准号:
    10551997
  • 财政年份:
    2019
  • 资助金额:
    $ 41.82万
  • 项目类别:
Role of necroptosis in colorectal cancer therapy
坏死性凋亡在结直肠癌治疗中的作用
  • 批准号:
    9882961
  • 财政年份:
    2019
  • 资助金额:
    $ 41.82万
  • 项目类别:
Molecular mechanism and preclinical development of BETi and PARPi combination therapy
BETi和PARPi联合疗法的分子机制和临床前开发
  • 批准号:
    10082442
  • 财政年份:
    2019
  • 资助金额:
    $ 41.82万
  • 项目类别:
Targeting defective necroptosis in colorectal cancer
靶向结直肠癌中的缺陷性坏死性凋亡
  • 批准号:
    10916808
  • 财政年份:
    2019
  • 资助金额:
    $ 41.82万
  • 项目类别:

相似海外基金

I-Corps: Translation Potential of a High Throughput Drug Discovery Platform for Protein Degraders
I-Corps:蛋白质降解剂高通量药物发现平台的转化潜力
  • 批准号:
    2419488
  • 财政年份:
    2024
  • 资助金额:
    $ 41.82万
  • 项目类别:
    Standard Grant
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
  • 批准号:
    10752555
  • 财政年份:
    2024
  • 资助金额:
    $ 41.82万
  • 项目类别:
Bivalent degraders of the understudied transcription factor TBXT for the rare cancer chordoma
正在研究的罕见癌症脊索瘤转录因子 TBXT 的二价降解剂
  • 批准号:
    10725821
  • 财政年份:
    2023
  • 资助金额:
    $ 41.82万
  • 项目类别:
Developing computational methods to identify of endogenous substrates of E3 ubiquitin ligases and molecular glue degraders
开发计算方法来鉴定 E3 泛素连接酶和分子胶降解剂的内源底物
  • 批准号:
    10678199
  • 财政年份:
    2023
  • 资助金额:
    $ 41.82万
  • 项目类别:
Targeted and directed degradation of oncogenic MYC mRNA with non-enzymatic peptide nucleic acid degraders (degPNAs)
使用非酶肽核酸降解剂 (degPNA) 靶向定向降解致癌 MYC mRNA
  • 批准号:
    EP/X024571/1
  • 财政年份:
    2023
  • 资助金额:
    $ 41.82万
  • 项目类别:
    Fellowship
Structural and Chemical Biology of Targeted Degraders of NSD2
NSD2 靶向降解剂的结构和化学生物学
  • 批准号:
    483396
  • 财政年份:
    2023
  • 资助金额:
    $ 41.82万
  • 项目类别:
    Operating Grants
Small-molecule degraders of STAT5
STAT5 的小分子降解剂
  • 批准号:
    10718129
  • 财政年份:
    2023
  • 资助金额:
    $ 41.82万
  • 项目类别:
Development of Small Molecule degraders of ILK for glioblastoma therapy
用于胶质母细胞瘤治疗的 ILK 小分子降解剂的开发
  • 批准号:
    EP/Y023390/1
  • 财政年份:
    2023
  • 资助金额:
    $ 41.82万
  • 项目类别:
    Fellowship
Structural and Chemical Biology of Targeted Degraders of NSD2
NSD2 靶向降解剂的结构和化学生物学
  • 批准号:
    488833
  • 财政年份:
    2023
  • 资助金额:
    $ 41.82万
  • 项目类别:
    Operating Grants
SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma
SIRT5 抑制剂和降解剂作为尤文肉瘤的新型治疗方法
  • 批准号:
    10739630
  • 财政年份:
    2023
  • 资助金额:
    $ 41.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了